The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

NCCN: U.S. cancer centers continue to see chemotherapy shortages

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The National Comprehensive Cancer Network has released a follow-up survey on the ongoing chemotherapy shortages: 72% of the centers surveyed continue to experience a shortage of carboplatin and 59% are still seeing a shortage of cisplatin. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone. The work will be presented at the 2024 ASCO Annual Meeting. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account